Vaccines and Related Biological Products Advisory Committee; Notice of Meeting, 5439-5440 [2014-01979]

Download as PDF Federal Register / Vol. 79, No. 21 / Friday, January 31, 2014 / Notices [FR Doc. 2014–02069 Filed 1–30–14; 8:45 am] BILLING CODE 4120–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Administration for Children and Families Notice of Meetings for Early Head Start-Child Care Partnerships Administration for Children and Families, HHS. ACTION: Notice of public meetings via webinar and telephone call-in. AGENCY: This public meeting is to obtain input on the creation of Early Head Start (EHS)-Child Care Partnerships that were authorized by the 2014 Omnibus Act, which was released on January 17, 2014. The purpose of this meeting is to provide an open door forum for public input in order to help the Department of Health and Human Services as we develop future planning activities. To help us best develop Early Head Start with local child care centers and family child care providers serving lowincome infants and toddlers, this notice invites the public to learn about partnerships and provide information that may assist the Agency at two public meetings held via webinar and telephone call-in. DATES: Two public meetings will be held on February 6, 2014, and February 7, 2014. The dates and times for each meeting will be: February 6, 2014: 4:00–5:00 p.m. EST February 7, 2014: 4:00–5:00 p.m. EST Registration and Additional Information: We request that interested persons register online with the Child Care Communications Management Center (CMC) to participate in one or more meetings via either webinar or by telephone. Interested persons may register for the February 6 meeting at: https://www3.gotomeeting.com/register/ 905737662, or the February 7 meeting at: https://www3.gotomeeting.com/ register/539737118. The contact at CMC is Karen Limsi, who can be reached by telephone at 240–399–8729 and by email at klimsi@ blhtech.com. Interested persons should register at least the day before the meeting in which they wish to participate. Each public meeting is scheduled for one hour, but will end sooner if participants have finished providing input before the time period expires. The format for the meetings is intended to allow participants to tkelley on DSK3SPTVN1PROD with NOTICES SUMMARY: VerDate Mar<15>2010 17:23 Jan 30, 2014 Jkt 232001 provide input and to respond to the input provided by others. We especially request input from entities interested in creating partnerships. To help interested individuals prepare for the meetings, we invite review of the 2014 Omnibus Appropriations bill. The full text is set forth at: https://www.gpo.gov/fdsys/pkg/ BILLS-113hr3547enr/pdf/BILLS113hr3547enr.pdf Written comments may be submitted at: EHS.CCPartnerships@acf.hhs.gov until Midnight February 7, 2014. SUPPLEMENTARY INFORMATION: The expansion of EHS-Child Care Partnerships is a key component in President Obama’s Early Learning Plan. These partnerships will extend the provision of high-quality early learning opportunities to more children from birth to age 3. Bolstering EHS-Child Care Partnerships promises to build a more seamless system for providing high-quality, full-day, full-year services to support children’s development and parents’ workforce needs. These public meetings will be primarily listening sessions for the Agency and potentially an opportunity for dialogue among participants. We believe that the input received at the public meetings will be most helpful in providing the Agency with background information and broadening awareness of relevant issues of potential partnerships between Early Head Start grantees to develop partnerships with local child care centers and family child care providers serving low-income infants and toddlers. We will not respond to presentations during the meetings and will not regard them as formal comments that must be addressed by the Agency. Dated: January 27, 2014. Linda K. Smith, Deputy Assistant Secretary for Early Childhood Development. [FR Doc. 2014–02035 Filed 1–30–14; 8:45 am] BILLING CODE 4184–40–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2014–N–0001] Vaccines and Related Biological Products Advisory Committee; Notice of Meeting AGENCY: Food and Drug Administration, HHS. ACTION: Notice. This notice announces a forthcoming meeting of a public advisory committee PO 00000 Frm 00072 Fmt 4703 Sfmt 4703 5439 of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public. Name of Committee: Vaccines and Related Biological Products Advisory Committee. General Function of the Committee: To provide advice and recommendations to the Agency on FDA’s regulatory issues. Date and Time: The meeting will be held on February 28, 2014, from approximately 8 a.m. to 4:20 p.m. Location: FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great Room (rm. 1503 B and C), Silver Spring, MD 20993–0002. Information regarding special accommodations due to a disability, visitor parking, and transportation may be accessed at https:// www.fda.gov/AdvisoryCommittees/ default.htm; under the heading ‘‘Resources for You,’’ click on ‘‘Public Meetings at the FDA White Oak Campus.’’ Please note that visitors to the White Oak Campus must enter through Building 1. For those unable to attend in person, the meeting will also be webcast. The link for the webcast is available at https://collaboration.fda.gov/vrbpac/ Contact Person: Prabhakara Atreya or Denise Royster, Center for Biologics Evaluation and Research (HFM–71), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301–827–0314, or FDA Advisory Committee Information Line, 1–800– 741–8138 (301–443–0572 in the Washington, DC area). A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the Agency’s Web site at https:// www.fda.gov/AdvisoryCommittees/ default.htm and scroll down to the appropriate advisory committee meeting link, or call the advisory committee information line to learn about possible modifications before coming to the meeting. Agenda: On February 28, 2014, the committee will meet in open session to hear an overview of the research program in the Laboratory of Respiratory Viral Diseases, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, FDA. The committee will then discuss and make recommendations on the selection of strains to be included in the influenza virus vaccine for the 2014 to 2015 influenza season. E:\FR\FM\31JAN1.SGM 31JAN1 tkelley on DSK3SPTVN1PROD with NOTICES 5440 Federal Register / Vol. 79, No. 21 / Friday, January 31, 2014 / Notices FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA’s Web site after the meeting. Background material is available at https://www.fda.gov/ AdvisoryCommittees/Calendar/ default.htm. Scroll down to the appropriate advisory committee meeting link. Procedure: On February 28, 2014, between approximately 8 a.m. and 9:30 a.m. and between approximately 10 a.m. and 4:20 p.m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person on or before February 21, 2014. Oral presentations from the public will be scheduled between approximately 2:20 p.m. and 3:20 p.m. on February 28, 2014. Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before February 13, 2014. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by February 14, 2014. Closed Committee Deliberations: On February 28, 2014, between approximately 9:30 a.m. and 10 a.m., the meeting will be closed to permit discussion where disclosure would constitute a clearly unwarranted invasion of personal privacy (5 U.S.C. 552b(c)(6)). The committee will discuss the report of the intramural research programs and make recommendations regarding personnel staffing decisions. Persons attending FDA’s advisory committee meetings are advised that the Agency is not responsible for providing access to electrical outlets. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical VerDate Mar<15>2010 22:14 Jan 30, 2014 Jkt 232001 disabilities or special needs. If you require special accommodations due to a disability, please contact Prabhakara Atreya or Denise Royster at least 7 days in advance of the meeting. FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at https://www.fda.gov/ AdvisoryCommittees/ AboutAdvisoryCommittees/ ucm111462.htm for procedures on public conduct during advisory committee meetings. Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2). Dated: January 27, 2014. Jill Hartzler Warner, Acting Associate Commissioner for Special Medical Programs. [FR Doc. 2014–01979 Filed 1–30–14; 8:45 am] BILLING CODE 4160–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Proposed Collection; 60-day Comment Request: National Institutes of Health Loan Repayment Programs In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Division of Loan Repayment, National Institutes of Health (NIH), will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. Written comments and/or suggestions from the public and affected agencies should address one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) the accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology. To Submit Comments and For Further Information: To request more SUMMARY: PO 00000 Frm 00073 Fmt 4703 Sfmt 4703 information on the proposed project or to obtain a copy of the data collection plans and instruments, contact: Steve Boehlert, Director of Operations, Division of Loan Repayment, National Institutes of Health, 6011 Executive Blvd., Room 206 (MSC 7650), Bethesda, Maryland 20892–7650. Steve may be contacted via email at BoehlerS@ od.nih.gov or by calling 301–451–4465. Formal requests for additional plans and instruments must be requested in writing. Comment Due Date: Comments regarding this information collection are best assured of having their full effect if received within 60 days of the date of this publication. Proposed Collection: National Institutes of Health Loan Repayment Programs. Type of Information Collection Request: Extension of a currently approved collection (OMB No. 0925– 0361, expiration date 06/30/14). Form Numbers: NIH 2674–1, NIH 2674–2, NIH 2674–3, NIH 2674–4, NIH 2674–5, NIH 2674–6, NIH 2674–7, NIH 2674–8, NIH 2674–9, NIH 2674–10, NIH 2674–11, NIH 2674–12, NIH 2674–13, NIH 2674–14, NIH 2674–15, NIH 2674– 16, NIH 2674–17, NIH 2674–18, and NIH 2674–19. Need and Use of Information Collection: The NIH makes available financial assistance, in the form of educational loan repayment, to M.D., Ph.D., Pharm.D., D.D.S., D.M.D., D.V.M., D.P.M., DC, and N.D. degree holders, or the equivalent, who perform biomedical or behavioral research in NIH intramural laboratories or as extramural grantees or scientists funded by domestic non-profit organizations for a minimum of 2 years (3 years for the General Research LRP) in research areas supporting the mission and priorities of the NIH. The AIDS Research Loan Repayment Program (AIDS–LRP) is authorized by Section 487A of the Public Health Service Act (42 U.S.C. 288–1); the Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds (CR–LRP) is authorized by Section 487E (42 U.S.C. 288–5); the General Research Loan Repayment Program (GR–LRP) is authorized by Section 487C of the Public Health Service Act (42 U.S.C. 288–3); the Clinical Research Loan Repayment Program (LRP–CR) is authorized by Section 487F (42 U.S.C. 288–5a); the Pediatric Research Loan Repayment Program (PR–LRP) is authorized by Section 487F (42 U.S.C. 288–6); the Extramural Clinical Research LRP for Individuals from Disadvantaged Backgrounds (ECR–LRP) E:\FR\FM\31JAN1.SGM 31JAN1

Agencies

[Federal Register Volume 79, Number 21 (Friday, January 31, 2014)]
[Notices]
[Pages 5439-5440]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-01979]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2014-N-0001]


Vaccines and Related Biological Products Advisory Committee; 
Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). At least one 
portion of the meeting will be closed to the public.
    Name of Committee: Vaccines and Related Biological Products 
Advisory Committee.
    General Function of the Committee: To provide advice and 
recommendations to the Agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on February 28, 2014, from 
approximately 8 a.m. to 4:20 p.m.
    Location: FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31 
Conference Center, the Great Room (rm. 1503 B and C), Silver Spring, MD 
20993-0002. Information regarding special accommodations due to a 
disability, visitor parking, and transportation may be accessed at 
https://www.fda.gov/AdvisoryCommittees/default.htm; under the heading 
``Resources for You,'' click on ``Public Meetings at the FDA White Oak 
Campus.'' Please note that visitors to the White Oak Campus must enter 
through Building 1.
    For those unable to attend in person, the meeting will also be 
webcast. The link for the webcast is available at https://collaboration.fda.gov/vrbpac/
    Contact Person: Prabhakara Atreya or Denise Royster, Center for 
Biologics Evaluation and Research (HFM-71), Food and Drug 
Administration, 1401 Rockville Pike, Rockville, MD 20852, 301-827-0314, 
or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-
0572 in the Washington, DC area). A notice in the Federal Register 
about last minute modifications that impact a previously announced 
advisory committee meeting cannot always be published quickly enough to 
provide timely notice. Therefore, you should always check the Agency's 
Web site at https://www.fda.gov/AdvisoryCommittees/default.htm and 
scroll down to the appropriate advisory committee meeting link, or call 
the advisory committee information line to learn about possible 
modifications before coming to the meeting.
    Agenda: On February 28, 2014, the committee will meet in open 
session to hear an overview of the research program in the Laboratory 
of Respiratory Viral Diseases, Division of Viral Products, Office of 
Vaccines Research and Review, Center for Biologics Evaluation and 
Research, FDA. The committee will then discuss and make recommendations 
on the selection of strains to be included in the influenza virus 
vaccine for the 2014 to 2015 influenza season.

[[Page 5440]]

    FDA intends to make background material available to the public no 
later than 2 business days before the meeting. If FDA is unable to post 
the background material on its Web site prior to the meeting, the 
background material will be made publicly available at the location of 
the advisory committee meeting, and the background material will be 
posted on FDA's Web site after the meeting. Background material is 
available at https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the appropriate advisory committee meeting 
link.
    Procedure: On February 28, 2014, between approximately 8 a.m. and 
9:30 a.m. and between approximately 10 a.m. and 4:20 p.m., the meeting 
is open to the public. Interested persons may present data, 
information, or views, orally or in writing, on issues pending before 
the committee. Written submissions may be made to the contact person on 
or before February 21, 2014. Oral presentations from the public will be 
scheduled between approximately 2:20 p.m. and 3:20 p.m. on February 28, 
2014. Those individuals interested in making formal oral presentations 
should notify the contact person and submit a brief statement of the 
general nature of the evidence or arguments they wish to present, the 
names and addresses of proposed participants, and an indication of the 
approximate time requested to make their presentation on or before 
February 13, 2014. Time allotted for each presentation may be limited. 
If the number of registrants requesting to speak is greater than can be 
reasonably accommodated during the scheduled open public hearing 
session, FDA may conduct a lottery to determine the speakers for the 
scheduled open public hearing session. The contact person will notify 
interested persons regarding their request to speak by February 14, 
2014.
    Closed Committee Deliberations: On February 28, 2014, between 
approximately 9:30 a.m. and 10 a.m., the meeting will be closed to 
permit discussion where disclosure would constitute a clearly 
unwarranted invasion of personal privacy (5 U.S.C. 552b(c)(6)). The 
committee will discuss the report of the intramural research programs 
and make recommendations regarding personnel staffing decisions.
    Persons attending FDA's advisory committee meetings are advised 
that the Agency is not responsible for providing access to electrical 
outlets.
    FDA welcomes the attendance of the public at its advisory committee 
meetings and will make every effort to accommodate persons with 
physical disabilities or special needs. If you require special 
accommodations due to a disability, please contact Prabhakara Atreya or 
Denise Royster at least 7 days in advance of the meeting.
    FDA is committed to the orderly conduct of its advisory committee 
meetings. Please visit our Web site at https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures 
on public conduct during advisory committee meetings.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: January 27, 2014.
Jill Hartzler Warner,
Acting Associate Commissioner for Special Medical Programs.
[FR Doc. 2014-01979 Filed 1-30-14; 8:45 am]
BILLING CODE 4160-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.